Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2021-01-30

FDA Approved: UPTRAVI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Uptravi (selexipag) to update the labeling; Uptravi is used for pulmonary arterial hypertension and is manufactured …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Uptravi (selexipag)

Snippet

SUPPL AP for UPTRAVI (SELEXIPAG)